George C. Prendergast, PhD, President and CEO, Lankenau Institute for Medical Research
C. Prendergast, PhD was appointed the President and CEO of the Lankenau
Institute for Medical Research (LIMR) in December 2004.
Prendergast is a graduate of the University of Pennsylvania, where as a
Benjamin Franklin Scholar he earned a Bachelor's degree magna cum laude
with distinction in Biochemistry. He received his Master’s degree in
Molecular Biophysics and Biochemistry from Yale University and his
doctorate in Molecular Biology from Princeton University.
After obtaining advanced training as an American Cancer Society
postdoctoral fellow at the Howard Hughes Medical Institute at NYU
Medical Center, he joined the Department of Cancer Research at Merck
Research Laboratories. In 1993, Prendergast was appointed assistant
professor and later associate professor at The Wistar Institute in
Philadelphia, where he was designated a Pew Scholar in the Biomedical
Sciences. Subsequently, he became the senior director of the Cancer
Research Group at the DuPont Pharmaceutical Company.
In 2002, he moved his research efforts at Wistar and DuPont to LIMR,
where he has pioneered new principles to prognose and treat advanced
cancers. In particular, Prendergast and his team at LIMR have developed
an exciting new immune therapy currently in Phase II clinical trials at
Main Line Health hospitals that stimulates a patient’s immune system to
destroy metastatic cancer cells.
Along with his scientific and leadership roles, Prendergast also serves
as the Editor-in-Chief of Cancer Research, the most highly cited journal
in the field. In leading LIMR, the research center for Main Line Health,
he has developed a world-class reputation marked by numerous
recognitions and honors.
For more information, call 1.866.CALL.MLH.